No headlines found.
ACCESS Newswire (Thu, 5-Feb 6:00 AM ET)
Globe Newswire (Fri, 30-Jan 9:00 AM ET)
Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel
Globe Newswire (Fri, 2-Jan 9:00 AM ET)
Globe Newswire (Tue, 23-Dec 9:00 AM ET)
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Scilex Holding Company trades on the NASDAQ stock market under the symbol SCLX.
As of March 23, 2026, SCLX stock price declined to $7.35 with 32,655 million shares trading.
SCLX has a beta of -0.24, meaning it tends to be less sensitive to market movements. SCLX has a correlation of 0.00 to the broad based SPY ETF.
SCLX has a market cap of $51.69 million. This is considered a Micro Cap stock.
Last quarter Scilex Holding Company reported $11 million in Revenue and -$22.17 earnings per share. This fell short of revenue expectation by $-37 million and missed earnings estimates by -$22.24.
In the last 3 years, SCLX traded as high as $591.51 and as low as $3.60.
The top ETF exchange traded funds that SCLX belongs to (by Net Assets): VTI, VXF, IWC, ITOT, URTY.
SCLX has underperformed the market in the last year with a price return of -25.1% while the SPY ETF gained +17.9%. SCLX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -48.8% and -13.3%, respectively, while the SPY returned -3.4% and -2.3%, respectively.
SCLX support price is $7.09 and resistance is $7.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SCLX shares will trade within this expected range on the day.
